Rising Incidence of Ischemic Reperfusion Injury to Augment the Ischemia Reperfusion Injury Therapeutics Market Growth
Ischemic reperfusion injury occurs due to the insufficient blood supply to the tissue. Ischemia reperfusion injury is the tissue damage caused when blood supply returns to tissue after a period of ischemia or lack of oxygen. Moreover, it is a critical medical condition that poses a major therapeutic challenge for physicians. Potential therapies include ischemic preconditioning, pharmacological treatment, and vitamin therapy or the use of medical gases, which could significantly help develop strategies to prevent ischemia reperfusion injury.
Market Dynamics:
Increasing incidence/prevalence of cardiovascular diseases,
such as myocardial infarction and stroke, worldwide is expected to propel the
growth of the ischemia reperfusion injury therapeutics market. For instance,
according to the World Health Organization, cardiovascular diseases are the
leading cause of death worldwide, accounting for around 17.9 million lives each
year.
Moreover, increasing number of tissue damage cases and
growing awareness among people about treatment of ischemia and reperfusion
injury is expected to augment the growth of the ischemia reperfusion injury therapeutics
market.
Introduction of novel drugs, increasing product approvals, and
rising research and development activities are also expected to fuel the growth
of the ischemia reperfusion injury therapeutics market. For instance, in
January 2021, the United States Food and Drug Administration (FDA) approved
Faron Pharmaceuticals’ New Drug Application for Traumakine, which can be used to
prevent systemic inflammatory response syndrome, which could be caused by
noninfectious insults such as ischemia-reperfusion injury.
Moreover, the increasing incidence of ischemic reperfusion
injury worldwide and strategic partnerships and collaborations of major players
are expected to drive the ischemia reperfusion injury therapeutics market
growth.
Competitive Analysis:
Major players operating in the ischemia reperfusion injury
therapeutics market are Gilead Sciences, Ensemble Therapeutics Corporation,
Erimos Pharmaceuticals, Curatis Pharma GmbH, Biomedica Management Corporation,
Bolder Biotechnology, Bayer AG, Angion Biomedica Corp., Antipodean
Pharmaceuticals, Amyndas Pharmaceuticals LLC, Stealth BioTherapeutics Inc.,
Zealand Pharma A/S, Prothix BV, Prolong Pharmaceuticals, Proteo, PledPharma AB,
Orexo, Pharming Group N.V., Opsona Therapeutics Limited, Nyken B.V., and Omeros
Corporation.
Major players in the market are focused on adopting various
strategies, such as partnerships and collaborations, to develop advanced drugs
and treatment in the market. For instance, in December 2020, LUCA Science announced
that it will collaborate with the Division of Cardiology, Field of Internal
Medicine, Nagoya University Graduate School of Medicine to initiate a joint
research on the development of mitochondrial therapy for cardiac
ischemic–reperfusion injury.
Comments
Post a Comment